Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here  to learn how we are responding.

Congress Materials

Medical Information
India
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for India Healthcare Professionals. Would you like to proceed?

I am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
SelectI am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
I am a patient/caregiver residing in IndiaNo, go back to the patient portal
SelectI am a patient/caregiver residing in IndiaNo, go back to the patient portal
Non-India residents click here.
The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Oral Presentation
Thomas SJ, Perez JL, Lockhart SP, Hariharan S, Kitchin N, Bailey R, Liau K, Lagkadinou E, Tureci O, Sahin U, Xu X, Dychter SS, Lu C, Gentile T, Gruber WC September 21, 2021 ESMO 2021 Other/Multi-Tumor

COVID-19 vaccine in participants with cancer: Subgroup analysis of efficacy/safety from a global Phase 3 randomized trial of the BNT162b2 (tozinameran) mRNA vaccine

View Presentation View Abstract Plain Language Summary
Poster
Alidoost M, Nickens DJ, Alhadab A March 18, 2022 ASCPT 2022 Other/Multi-Tumor

Machine Learning (ML) Methods for Progression-Free Survival (PFS) and Overall Survival (OS) Prediction: Reanalysis of JAVELIN Head and Neck 100 Data

View Presentation
Poster
Zhou L, Liao K, Yin D, Chen X, Masters JC March 18, 2022 ASCPT 2022 Other/Multi-Tumor

Population Pharmacokinetics of Sasanlimab in Patients With Solid Tumors: Modeling-Based Analysis of Data From the First-in-Patient Trial

View Presentation
Poster
Laetsch TW, Janeway KA, Hawkins DS, Juszczak-Kosela K, Muscal JA, Collier AB June 5, 2022 ASCO 2022 Other/Multi-Tumor

Randomized Phase 2 Study to Evaluate Palbociclib (IBRANCE®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Ewing Sarcoma 

View Presentation View Abstract Plain Language Summary
Poster
Chawla SP, Kelly CM, Gordon EM, Quon DV, Moradkhani A, Chua VS, Thompson TM, Scheuber A, Bruns I, Allgood VE, Movva S June 5, 2022 ASCO 2022 Other/Multi-Tumor

TTI-621-03: A Phase 1/2 Study of TTI-621 in Combination with Doxorubicin in Patients with Unresectable or Metastatic High-Grade Leiomyosarcoma (LMS) 

View Presentation